TY  - JOUR
AU  - Elez, Elena
AU  - Gomez-España, Maria Auxiliadora
AU  - Gravalos, Cristina
AU  - Garcia-Alfonso, Pilar
AU  - Ortiz-Morales, Maria Jose
AU  - Losa, Ferran
AU  - Diaz, Inmaculada Ales
AU  - Graña, Begoña
AU  - Toledano-Fonseca, Marta
AU  - Valladares-Ayerbes, Manuel
AU  - Polo, Eduardo
AU  - Salgado, Mercedes
AU  - Martinez de Castro, Eva
AU  - Safont, Maria Jose
AU  - Salud, Antonieta
AU  - Ruiz-Casado, Ana
AU  - Tabernero, Josep
AU  - Riesco, Maria Del Carmen
AU  - Rodriguez-Ariza, Antonio
AU  - Aranda, Enrique
PY  - 2021
DO  - 10.1038/s41416-021-01638-w
UR  - http://hdl.handle.net/10668/19521
T2  - British journal of cancer
AB  - Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated. We assessed aflibercept plus FOLFIRI,...
LA  - en
PB  - Nature
KW  - Biomarkers
KW  - Colorectal neoplasms
KW  - Fluorouracil
KW  - Vascular endothelial growth factor A
KW  - Antineoplastic combined chemotherapy protocols
KW  - Biomarkers
KW  - Camptothecin
KW  - Colorectal neoplasms
KW  - Fluorouracil
KW  - Humans
KW  - Irinotecan
KW  - Leucovorin
KW  - Receptors, vascular endothelial growth factor
KW  - Recombinant fusion proteins
KW  - Vascular endothelial growth factor A
TI  - Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
TY  - research article
VL  - 126
ER  -